Tumor lysis syndrome in a patient with metastatic colon cancer after treatment with oxaliplatin and 5-Fu  by Tseng, Ruo-Han et al.
lable at ScienceDirect
Journal of Cancer Research and Practice 3 (2016) 124e127Contents lists avaiJournal of Cancer Research and Practice
journal homepage: http : / /www.journals .elsevier .com/journal-of -cancer-
research-and-pract iceCase reportTumor lysis syndrome in a patient with metastatic colon cancer after
treatment with oxaliplatin and 5-Fu
Ruo-Han Tseng a, *, Ching-Hsu Wu a, Kuan-Lin Wu b, Guan-Min Lai a, Jen-Tsun Lin a
a Department of Hematology and Oncology, Changhua Christian Hospital, Changhua, Taiwan
b Department of Medical Imaging, Changhua Christian Hospital, Changhua, Taiwana r t i c l e i n f o
Article history:
Received 28 October 2015
Received in revised form
5 February 2016
Accepted 11 March 2016





5-Fu* Corresponding author. Department of Hematolo
Christian Hospital, No. 135 Nanxiao St., Changhua
Taiwan.
E-mail address: gwynn514@gmail.com (R.-H. Tsen
Peer review under responsibility of The Chinese O
http://dx.doi.org/10.1016/j.jcrpr.2016.03.001
2311-3006/Copyright © 2016, The Chinese Oncology
creativecommons.org/licenses/by-nc-nd/4.0/).a b s t r a c t
Tumor lysis syndrome in solid tumors is a rare occurrence, with a poor prognosis. We present the case of
a patient of recurrent colon cancer who received chemotherapy with FOLFOX regimen (lencovorin,
ﬂuorouracil, and oxaliplatin) with subsequent tumor lysis. We present a recurrent rectal cancer patient
suffered from tumor lysis syndrome after salvage FOLFOX regimen. After treat with CVVH with improved
conscious status. In this case report, we had review the tumor lysis in solid tumor.
Copyright © 2016, The Chinese Oncology Society. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Tumor lysis syndrome is frequently observed in hematologic
cancer or in rapidly growing and bulky tumors. The symptoms of
this condition include decreased urine output, hyperkalemia,
hyperphosphatemia, hypocalcemia and hyperuricemia and may be
accompanied by metabolic acidosis, arrhythmia or even seizure.1e5
Tumor lysis syndrome rarely occurs in solid tumors but it can
frequently be observed in sensitive bulky solid tumors post-
treatment with chemotherapy or radiotherapy. Treatment for
acute tumor lysis includes renal replacement therapy in patients
with severe oliguria or anuria, persistent hyperkalemia, hyper-
phosphatemia and with a calcium-phosphate product S70 mg2/
dL.22. Case report
We herein report on a 65-year-old male with a past history of
rectal adenocarcinoma pT3N2M0 in 2002, who had a low anteriorgy and Oncology, Changhua
City, Chaghua County 500,
g).
ncology Society.
Society. Production and hosting byresection procedure and received concurrent chemoradiotherapy
with a 21-course FOLX regimen (5-FU and leucovorin).
Results from computerized tomography showed tumor recur-
rence in the pelvic region with ﬁstula formation from the urinary
bladder, extending into the presacral space (Figs. 1e4). Thereafter,
chemotherapy with FOLFOX (leucovorin, ﬂuorouracil, oxaliplatin)
regimen (ﬁrst cycle chemotherapy after noted recurrent) was
initiated. Upon completion of chemotherapy (exact chemotherapy
regimen with: oxaliplatin 160 mg (85 mg/m2), 5-FU 2800 mg
(1500 mg/m2) for 1 day and leucovorin 200 mg), the patient
complained of chest tightness followed by alternating periods of
consciousness and ventricular tachycardia requiring
cardiopulmonary-cerebral resuscitation and deﬁbrillation.
Following his initial resuscitation, the patient was admitted to the
intensive care unit and laboratory data showed hyperkalemia,
acute kidney injury and oliguria. After 1 day, laboratory data
showed persistent hyperammonemia (ammonia 304 ug/dL), which
elevated our suspicion that there was complicit drug toxicity due to
5-FU. However, the patient's high potassium levels persisted, along
with ventricular arrhythmia, after which he received deﬁbrillation.
Follow-up data on day 4 showed the following: hyperuricemia uric
acid: 15.9 mg/Dl (normal range: 4.8e8.7 mg/dL) and hypocalcemia
Ionized Ca: 1.01 mmol/L (normal range:1.09e1.30 mmol/L) and
serum creatinine increased from 2.14 to 3.14 mg/dL from day 4 to
day 5 with normal serum phosphorus level. The patient's condition
was stable before the initiation of chemotherapy. Given the fact thatElsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
Fig. 1. Rectal cancer post anterior resection and CCRT with tumor recurrence.
Fig. 3. 1. Rectovesical ﬁstula; 2. Sacrum lytic lesion suspected due to bone metastasis
or post CCRT bone necrosis; 3. Perineal muscle with tumor invasion.
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with tumor lysis syndrome as evidenced by hyperkalemia with
ventricular ﬁbrillation twice, hypocalcemia, hypruricemia, and
poor renal function, the typical electrolyte changes may not be as
“typical” as suggested. The dose of chemotherapy (FOLFOX) had
been adjusted before the initiation of treatment.
Based on these ﬁndings, tumor lysis syndrome was strongly
suspected. After treatment with rasburicase for hyperuricemia, the
patient's condition improved and increased urine output was
noted. When this patient ﬁrst presented to our facility, we did not
consider the possibility of tumor lysis due to the rarity of the dis-
ease. Not until the patient twice exhibited ventricular ﬁbrillations
with hyperkalemia was tumor lysis conﬁrmed. However, the HD
was delayed due to the family's concern about the patient's poor
condition. He then received renal replacement therapy (continuous
veno-venous hemoﬁltration from day 7 to day 10), regaining con-
sciousness on day 9.
Subsequently, the patient was successfully extubated on day 11.
By that point, the ﬁnal creatinine level was back to 1.41mg/dL. After
this episode, we had shifted chemotherapy to capecitabine
1000 mge1500 mg daily, to maintain an antitumor effect andFig. 2. Residual bladder with some air-ﬂuid level due to rectovesical ﬁstula.diminish poor activity. The patient received another course of
chemotherapy Irinotecan 300 mg (180 mg/m2), leucovorin 600 mg
(400 mg/m2), 5-FU 2000 mg (1500 mg/m2), after which this
treatment scenario concluded. To date, no additional tumor lysis
has occurred and the patient is doing well. Our facility did not
performed any follow-up imaging arising from the fact that the
patient had just received two courses (with one incomplete) of
chemotherapy.
3. Discussion
Tumor lysis syndrome can be classiﬁed in terms of both clinical
and laboratory parameters, according to the Cairo and Bishop
grading system. First, at least two or more metabolic abnormalities
must be noted simultaneously. Second, a 25% change in the baseline
laboratory data should not be considered as a criterion. Third, any
symptomatic hypocalcemia should constitute the symptoms of
clinical tumor lysis syndrome.1 Our patient met the criteria of both
clinical and laboratory parameters for tumor lysis syndrome (clin-
ically: cardiac dysrhythmia, disturbance in consciousness, and
increased serum creatinine level; laboratory: hyperuricemia, hy-
pocalcemia, and hyperkalemia). Tumor lysis syndrome is most
frequently observed during treatment of hematologicmalignancies,
usually leukemia and lymphoma.6 Most of the hematologic tumors
associated with tumor lysis syndrome are poorly differentiated
lymphomas, such as Burkitt's lymphoma, and leukemias such as
acute lymphoblastic leukemia and acute myeloid leukemia. Tumor
lysis syndrome is rare in solid tumors and more frequently found in
bulky tumors and chemotherapy sensitive cancers such as small cell
lung cancer, and widespread gastrointestinal tract adenocarcinomaFig. 4. 1. Post operation residual rectum; 2. Perisarcum muscle with tumor invasion.
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tumor lysis syndrome in solid tumors post-radiotherapy or even
target therapy, such as metastatic gestational trophoblastic
neoplasia, renal cell carcinoma, and metastatic transitional cell
carcinoma.7e10 The prognosis of tumor lysis syndrome is poor in the
case of solid tumors compared to hematology malignancy, which
may be due to the frequent lack of early recognition and preven-
tion.11 One study mentioned tumor lysis syndrome occurring in
solid tumor patients typically manifests a later onset than in he-
matological malignancies, which may be related to the more syn-
chronous kinetics of lymphomyeloproliferative disorders cells than
solid tumor cells.12 The patient had suffered from chemotherapy-
associated hyperammonia complicated with tumor lysis syn-
drome, as indicated by ventricular ﬁbrillation caused by hyper-
kalemia and hyperuricemia. We do not refer to this scenario as “late
onset tumor lysis syndrome”. In fact, we believe the tumor lysis
probably occurred after the chemotherapy but was masked by the
hyperammonia that might be caused by 5-FU. In the very begin-
ning, we did not contemplate the possibility of tumor lysis since it is
rare - especially for the FOLFOX regimen. Not until the patient had
twice suffered ventricular ﬁbrillations with hyperkalemia did we
think the possibility of tumor lysis.
In this case report, we described a rare case of tumor lysis
syndrome associated with the FOLFOX regimen and further stress
the importance of additional prophylaxis for the huge tumor
burden.13e16
Our patient's hyperammonemia may be due to cardiogenic
shock, post cardio-pulmonary-cerebral resuscitation, shock liver or
tumor lysis. The causes of hyperammonemia include increased
ammonia production (such as infection, GI bleeding, trauma, can-
cer, or chemotherapy), decreased ammonia excretion (such as acute
liver failure, cirrhosis), and drug-induced hyerammonemia.17 Also,
a previous case report had mentioned rectovesical and ileal
ﬁstulae-related hyperammonemia encephalopathy.18 We had
repeat ammonia data after this acute episode, which showed the
ammonia numbers to be around 90ug/dL. We suggested that the
patient with chronic hyperammonemia and worsened by the shock
episode and 5-FU was continuous-infusion related.
To the best of our knowledge, this is the second case report in
the literature about tumor lysis syndrome occurring in a colon
cancer patient treated with FOLFOX regimen.11 However, our case is
unique and quite different from the quoted paper. First, our patient
suffered from hyperammonia that could be aggravated by 5-FU,
which was simultaneously complicated with tumor lysis syndrome
and resulted in a change of consciousness and critical condition. In
the very beginning, we did not think of the possibility of tumor lysis
since it is rare. Not until the patient had ventricular ﬁbrillations
twice with hyperkalemia did we think of the possibility of tumor
lysis. The delayed use of CVVH can still save a patient's life. How-
ever, our patient received only one day of chemotherapy.
Treatment of tumor lysis syndrome includes hydration and
control of hyperuricemia, hyperkalemia, and diuresis for a balanced
ﬂuid status.
Once it is identiﬁed, renal replacement therapy is essential for
emergency tumor lysis treatment. In this case, we prescribed renal
replacement therapy at day 7 after chemotherapy with preserved
renal function and corrected metabolic encephalopathy. A earlier
study suggested that continuous veno-venous hemodiaﬁltration is
more effective in reducing the phosphate level than conventional
hemodialysis.19 The drastic response even after a delay in per-
forming dialysis in our case suggests that there may be chemo-
therapy related toxicity post chemotherapy, and continuous
dialysis for up to 2 weeks may be needed.
Cardiac echography was arranged on day 3 and showed regional
wall abnormality with reduced LV systolic function (LVEF: 23%).Regarding differential tumor lysis syndrome and 5-FU related car-
diotoxicity, we had reviewed this patient's risk in conjunction with
the chemotherapy regimen. The 5-FU related cardiotoxicity is a rare
complication with the incidence around 1.6e3% in the short
regimen, and 7.6e18% in the longer regimen.20
We suspected that 5-FU related cardiotoxicity was less likely
because the 5-FU dose in our regimenwas only a median dose, and
the patient had not even completed the 1st day of the 5-FU
regimen. The cardiac toxicity on the patient may be due to both
chronic kidney disease and suspected congestive heart failure and
aggravated on moderate dose 5-fu (but lacking data for baseline
heart function).21
Oxaliplatin sensitivity is related to cytokines and histamine, and
often presents with predominantly mild symptoms of ﬂushing,
heart rate and blood pressure alternation, dyspnea and chest
discomfort. Symptoms usually subsided after discontinuation of
drug and administration of steroid and antihistamine.22 For the
above reason, we suggested oxaloplatin is less likely in our patient.
4. Conclusions
This is only the second case report of a patient with colon cancer
treated with the FOLFOX regimen who suffered from acute tumor
lysis syndrome. and the ﬁrst case in which delayed renal replace-
ment therapy was administered resulting in improved conscious-
ness and renal function, corrected arrhythmia and stable vital signs.
Arising from the results of our treatment, we suggest renal
replacement therapy be considered by other clinicians for tumor
lysis because it is helpful in the delayed stage.
5. Consent
Inform consent was obtained from the patient, who understood
the unique clinical course and the possibility of further treatment.
Conﬂict of interest
There is no conﬂict of interest in the case report.
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